Category
Longevity & cellular
Bioregulators, mitochondrial peptides and NAD+ chemistry. Mixed and easy to misread — some members are long-established molecules with enormous general literature, which is not the same as evidence for the longevity use they are sold for.
What the record holds for this category
6
Compounds tracked
1
With an FDA-approved product
3
With no registered human study
164
Registered studies, all members
Every compound in this category
Ordered by how many people read the Wikipedia article each month, which measures attention and nothing else. The evidence column is what is actually known.
| Compound | FDA status | Human studies | Evidence | Readership |
|---|---|---|---|---|
| NAD+ | Research only | 71 | BReached phase 3 or 4, not approved | 19,297 |
| Glutathione | Research only | 72 | BReached phase 3 or 4, not approved | 14,776 |
| Epithalon | Research only | 0 | XNo registered human study | 5,080 |
| SS-31 | Approved | 21 | AAn approved product exists | 1,883 |
| FOXO4-DRI | Research only | 0 | XNo registered human study | 1,079 |
| Humanin | Research only | 0 | XNo registered human study | 671 |
Compare within this category
These pairs are the most-read members, picked mechanically. Pairing is not a recommendation and says nothing about which is preferable.
Reading on these compounds
Categories are editorial groupings by mechanism — they are not medical classifications, and membership is not a claim that a compound does what the group name suggests. Study counts include only trials whose registered intervention names the compound. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. How this is put together.